成功使用克里佐替尼为向治疗儿科不可切割的ERC1::ALK融合肉瘤
Megan L Wood1, Julie C Fanburg-Smith2, James M Brian3
1Department of Obstetrics and Gynecology, Stony Brooke University, New York, NY.
Journal of pediatric hematology/oncology
|December 15, 2023
概括
无细胞淋巴瘤激酶 (ALK) 融合瘤很少见. 作为ALK抑制剂的克里佐替尼 (crizotinib) 在患有新型ALK融合肉瘤的儿科患者中实现了完全康复,显示了其治疗这种罕见癌症的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 无塑性淋巴瘤激酶 (ALK) 融合瘤代表了瘤的一个罕见子集.
- 这些瘤与铁氨酸激酶RAS::MAPK通路有关.
- 新兴研究表明,这些合并在理论上是可针对的.
研究的目的:
- 描述一种新型ALK融合肉瘤的临床病理特征和治疗结果.
- 评估crizotinib在治疗这种罕见的肉瘤亚型中的疗效.
- 评估对ALK向治疗的长期反应.
主要方法:
- 一个15个月大的男性患有右手肉瘤的病例报告.
- 鉴定了一种新型ELKS/RAB6-相互作用/CAST家族成员1-不对齐的ALK融合.
- 用口服单疗法治疗crizotinib,一个ALK氨酸激酶抑制剂.
主要成果:
- 在克里佐替尼治疗10个月内实现了完全的放射和临床解像度.
- 在选择性停止药物后,观察到持续反应超过12个月.
- 这种治疗证明了对一种不可切除的新型ALK融合肉瘤的成功治疗.
结论:
- 克里佐替尼 (crizotinib) 是一种有效的口服单疗法,用于新型ALK融合瘤.
- 用ALK抑制剂进行向治疗可以使儿科患者的病情完全消失.
- 这一案例突出了针对罕见的融合驱动型肉瘤的ALK向治疗的潜力.
更多相关视频
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
9.6K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
